Trial · NCT03619213
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. | Dapa 10 mg | 512 | Participants | ||
| Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. | Placebo | 610 | Participants | ||
| Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation | Dapa 10 mg | 381 | Participants | ||
| Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation | Placebo | 440 | Participants | ||
| Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) | Dapa 10 mg | 815 | Number of events | ||
| Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) | Placebo | 1057 | Number of events | ||
| Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation | Dapa 10 mg | 605 | Number of events | ||
| Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation | Placebo | 782 | Number of events | ||
| Change From Baseline in the KCCQ Total Symptom Score at 8 Months | Dapa 10 mg | 8.3 | Standard Deviation 20.3 | Scores on a scale | |
| Change From Baseline in the KCCQ Total Symptom Score at 8 Months | Placebo | 5.2 | Standard Deviation 21.1 | Scores on a scale | |
| Subjects Included in the Endpoint of Cardiovascular Death | Dapa 10 mg | 231 | Participants | ||
| Subjects Included in the Endpoint of Cardiovascular Death | Placebo | 261 | Participants | ||
| Subjects Included in the Endpoint of All-cause Mortality | Dapa 10 mg | 497 | Participants | ||
| Subjects Included in the Endpoint of All-cause Mortality | Placebo | 526 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03619213/results